share_log

Virpax Pharmaceuticals | DEFA14A: Others

Virpax Pharmaceuticals | DEFA14A: Others

Virpax制药 | DEFA14A:其他
美股SEC公告 ·  07/08 16:38
Moomoo AI 已提取核心信息
Virpax Pharmaceuticals, Inc. has issued a supplement to its definitive proxy statement, detailing significant changes ahead of its 2024 Annual Meeting of Stockholders scheduled for July 29, 2024. The supplement, dated July 5, 2024, follows the company's entry into a Securities Purchase Agreement with an institutional investor, resulting in a $2.5 million financing deal. This transaction prompted a reorganization of the company's Board of Directors, with the resignation of five directors and the appointment of four new ones, including Judy Su, Jatinder Dhaliwal, Katharyn Field, and Gary Herman. Dr. Jeffrey Gudin's resignation as a Class III director led to Gary Herman's appointment in his stead, with Herman now standing for reelection at the upcoming Annual Meeting. The Board has been restructured into...Show More
Virpax Pharmaceuticals, Inc. has issued a supplement to its definitive proxy statement, detailing significant changes ahead of its 2024 Annual Meeting of Stockholders scheduled for July 29, 2024. The supplement, dated July 5, 2024, follows the company's entry into a Securities Purchase Agreement with an institutional investor, resulting in a $2.5 million financing deal. This transaction prompted a reorganization of the company's Board of Directors, with the resignation of five directors and the appointment of four new ones, including Judy Su, Jatinder Dhaliwal, Katharyn Field, and Gary Herman. Dr. Jeffrey Gudin's resignation as a Class III director led to Gary Herman's appointment in his stead, with Herman now standing for reelection at the upcoming Annual Meeting. The Board has been restructured into three classes, with the current composition being seven directors. The company has also updated its proxy card to reflect the nominee changes and advises stockholders who have already voted and do not wish to change their vote that no further action is required. The proxy materials, including the amended notice, proxy statement, supplement, updated proxy card, and the 2023 Annual Report, are available at www.proxyvote.com.
Virpax药品公司已就其2024年股东年会的重大变化发布了补充投票声明书。该补充声明书于2024年7月5日发布,紧随公司与一家机构投资者签订证券购买协议,达成250万美元的融资协议。这项交易促使公司的董事会重新组织,五名董事辞职并任命了四名新董事,包括朱迪·苏(Judy Su)、雅廷德尔·达利瓦尔(Jatinder Dhaliwal)、凯瑟琳·菲尔德(Katharyn Field)和加里·赫尔曼(Gary Herman)。杰弗里·古丁博士的辞职使得加里·赫尔曼接替他成为三号董事,并参加即将到来的年会竞选连任。董事会已被重新分为三个类,当前成员为七名董事。公司还更新了其代理卡,以反映提名人的变更,并建议已经投票且不希望更改投票的股东不需要采取进一步行动。代理材料,包括修改后的通知书、投票声明书、补充声明书、更新的代理卡以及2023年年度报告,均可在www.proxyvote.com上获取。
Virpax药品公司已就其2024年股东年会的重大变化发布了补充投票声明书。该补充声明书于2024年7月5日发布,紧随公司与一家机构投资者签订证券购买协议,达成250万美元的融资协议。这项交易促使公司的董事会重新组织,五名董事辞职并任命了四名新董事,包括朱迪·苏(Judy Su)、雅廷德尔·达利瓦尔(Jatinder Dhaliwal)、凯瑟琳·菲尔德(Katharyn Field)和加里·赫尔曼(Gary Herman)。杰弗里·古丁博士的辞职使得加里·赫尔曼接替他成为三号董事,并参加即将到来的年会竞选连任。董事会已被重新分为三个类,当前成员为七名董事。公司还更新了其代理卡,以反映提名人的变更,并建议已经投票且不希望更改投票的股东不需要采取进一步行动。代理材料,包括修改后的通知书、投票声明书、补充声明书、更新的代理卡以及2023年年度报告,均可在www.proxyvote.com上获取。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息